Takahiro Kuragano
Overview
Explore the profile of Takahiro Kuragano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nakanishi M, Goto A, Iwasaki T, Nakanishi T, Kuma A, Nanami M, et al.
BMC Nephrol
. 2023 Dec;
24(1):373.
PMID: 38102596
Background: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with chronic kidney disease (CKD) and could be related to oxidative stress. Vascular calcification (VC) has...
12.
Kuragano T, Okami S, Tanaka-Mizuno S, Uenaka H, Kimura T, Ishida Y, et al.
Kidney360
. 2023 Jul;
4(9):e1223-e1235.
PMID: 37424063
No abstract available.
13.
Fujii H, Hamano T, Tsuchiya K, Kuragano T, Joki N, Tsuruya K, et al.
Int J Cardiol
. 2023 Jan;
375:110-118.
PMID: 36592827
Background: Responsiveness to erythropoiesis-stimulating agents (ESAs) has been reported to be associated with increased cardiovascular disease (CVD) and mortality in patients undergoing hemodialysis (HD). However, the association between hyporesponsiveness to...
14.
Iwasaki T, Mizusaki K, Masumoto M, Minagawa Y, Azuma K, Furukawa T, et al.
BMC Nephrol
. 2022 Jul;
23(1):262.
PMID: 35870879
Background: TAFRO syndrome is an acute or subacute systemic inflammatory disease with no apparent cause, presenting with fever, generalized edema, thrombocytopenia, renal damage, anemia, and organ enlargement. Interleukin-6, vascular endothelial...
15.
Masumoto M, Kuragano T, Takata C, Fukui R, Mihara Y, Okamoto R, et al.
Int Urol Nephrol
. 2021 Aug;
54(5):1079-1084.
PMID: 34390438
Purpose: Previous studies reported that the long-acting erythropoiesis-stimulating agent (ESA) significantly suppresses the expression of hepcidin, which regulates iron availability. In this study, we compared the iron availability for erythropoiesis...
16.
Nagasawa Y, Nanami M, Kuragano T, Ishihara M
Hypertens Res
. 2021 Aug;
44(11):1540-1542.
PMID: 34385689
No abstract available.
17.
Iwasaki T, Fujimori A, Okada S, Hanawa N, Kuragano T
Iran J Kidney Dis
. 2021 Jul;
15(4):306-313.
PMID: 34279002
Introduction: Although several investigators have reported the relationship between bone mineral density (BMD) and mortality in patients on hemodialysis, it is unclear BMD of which site is most strongly associated...
18.
Aichi M, Kuragano T, Iwasaki T, Ookawa S, Masumoto M, Mizusaki K, et al.
ASAIO J
. 2021 Jun;
68(2):297-302.
PMID: 34172640
We compared the effects on the nutritional condition and health-related quality of life (HR-QoL) of the treatment of patients with on-line hemodiafiltration (OL-HDF) and conventional hemodialysis (CHD) using a superflux...
19.
Iwasaki T, Fujimori A, Nakanishi T, Okada S, Hanawa N, Hasuike Y, et al.
BMC Nephrol
. 2021 Apr;
22(1):124.
PMID: 33832448
Background: Decreased erythropoietin levels and impaired iron metabolism due to excessive hepcidin levels are responsible for renal anaemia in patients undergoing haemodialysis. Recently, erythroferrone (ERFE) has been identified as a...
20.
Nakanishi T, Kuragano T
Clin Kidney J
. 2021 Feb;
14(1):59-69.
PMID: 33564406
A randomized controlled trial,the Proactive IV Iron Therapy in Haemodialysis Patients (PIVOTAL), has recently shown that a high-dose ('proactive') intravenous iron regimen was superior to a low-dose ('reactive') regimen for...